Page last updated: 2024-10-25

desipramine and Medulloblastoma

desipramine has been researched along with Medulloblastoma in 1 studies

Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.

Medulloblastoma: A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Carignani, C1
Corsi, M1

Other Studies

1 other study available for desipramine and Medulloblastoma

ArticleYear
Inhibition of SK3 channels in the TE671 human medulloblastoma cell line by desipramine and imipramine.
    European journal of pharmacology, 2002, Jul-19, Volume: 448, Issue:2-3

    Topics: Desipramine; Dose-Response Relationship, Drug; Humans; Imipramine; Medulloblastoma; Membrane Potenti

2002